FrontPage is India's Stock Market Social Network
Join 50,000+ Traders and Investors

GLAXO

1,380.35
+7.4 (0.54%)
Updated 03:29 05/06 IST

GLAXO Buy or Sell - FrontPage Forums

0 Users have submitted 0 trade ideas of Rs. 0 for GLAXO
Disclaimer
0% Bullish
0% Bearish

GLAXO Ratings

Long term GLAXO rating by FrontPage users
3/5 (1 Ratings)
Find answers to all your questions on live GLAXO message board: Is GLAXO buy or sell? Should I buy GLAXO shares? Why are GLAXO shares falling? Should I invest in GLAXO stock?

GLAXO Share Price Discussion

Reputation: 11,963 • May 21 9:00 AM

Karvy Stock Broking target on GLAXO
Date: 19-May-20 Broker: Karvy Stock Broking Price @ Call: 1390.74 Target: 1292 Recommendation: SELL
Like
Reply

*Result Highlight*
Glaxosmithkline Pharmaceuticals Ltd. Q4 Cons: Net profit down -6% at Rs. 138.07 cr. Vs Rs. 146.81 cr. (YoY) and Revenue up 3.3% at Rs. 775.8 cr. Vs Rs. 750.81 cr. (YoY)
Board of Directors recommend a Dividend of Rs 40 per equity share of face value of Rs.10 eac...
Read more...
3
Reply
Reputation: 3,179 • May 18 2:18 AM
GlaxoSmithKline Pharma Q4 net profit declines 6% to Rs 138 crore
For the fiscal year ended March this year, the company posted a net profit of Rs 93.20 crore as against Rs 445.39 crore in the previous fiscal, the filing said.
Moneycontrol
Like
Reply
Reputation: 3,179 • May 18 2:08 AM
Trade Setup for Tuesday: Top 15 things to know before Opening Bell
Key support level for Nifty is placed at 8,700.57, followed by 8,577.88. If the index moves up, key resistance levels to watch out for are 9,052.12 and 9,280.98.
Moneycontrol
Like
Reply
Reputation: 13,291 • May 6 11:06 AM

Sources :
Glaxo to sell HUL shares via Block deals tomorrow
Deal likely at Rs 1850-1950 per share
Glaxo to sell nearly 6% stake in HUL
Glaxo looks to raise over Rs 25,000 crores via HUL block deal
Like
Reply (3)
Latest replies
tstaamir @tstaamir
May 6 1:25 AM

Yes sir so tomorrow its a red for HUL
King999 @king999
May 6 1:44 AM

everyday is red for HUL HAHAHA
tstaamir @tstaamir
May 7 5:39 AM

😂😂😂
Reputation: 3,179 • May 5 12:58 PM
Hot Stocks | Glaxo Pharma, M&M, Tata Comm three buy ideas for short term
In the week gone by, Nifty took out the crucial resistance of 9,390, which will interchange its role as immediate resistance.
Moneycontrol
Like
Reply
Reputation: 3,179 • Apr 15 12:38 PM
Hot Stocks | Three stock ideas for the short term
By surpassing the resistance of 8,600 in the previous week, Nifty also confirmed the bullish inverse head and shoulder pattern breakout on the daily line charts.
Moneycontrol
Like
Reply
Reputation: 3,179 • Apr 12 6:33 AM
USFDA asks companies to remove ranitidine products; will Indian regulator review its stand?
The USFDA is investigating presence N-Nitrosodimethylamine, a probable cancer causing impurity in ranitidine products.
Moneycontrol
Like
Reply
GLAXO

Type
Buy
Instrument
GLAXO
Entry Price
₹1,198
Price@Trade
₹1,198
Target Price
₹1,280
Stop Price
₹1,150
Valid Till
Apr 16, 2020 3:20 AM
Margin
₹1,198 approx for 1 Qty
Status
Exited
Exit Price
₹1,242.85
Net P&L
+₹44.81 (+3.74%)
Like
Reply (1)
Latest replies

Update
Exited
Exit Price
₹1,242.85
Net P&L
+₹44.81 (+3.74%)
Reputation: 3,179 • Mar 19 10:18 AM
Coronavirus pandemic | Pharma companies ask sales representatives to work from home
India's largest drug maker Sun Pharma which has field force 9,500 plus covering over 400,000 doctors in every nook and corner of the country said it is encouraging employees in the field globally to work from home.
Moneycontrol
Like
Reply
Reputation: 3,179 • Mar 9 2:23 AM
Pharma sales see rebound in February on back of respiratory drugs
Eight of the top 10 therapies registered a growth of more than 10 percent.
Moneycontrol
Like
Reply
Reputation: 3,179 • Mar 5 3:43 AM
24 companies in BSE500 index reported net loss in Q3; what should you do with the stocks?
Among the top 500 companies, over 20 companies turned loss-making in the December quarter, data from AceEquity showed
Moneycontrol
Like
Reply
Reputation: 3,179 • Mar 4 11:18 AM
MNC drug body OPPI names Sharad Tyagi as President
Tyagi is currently Managing Director, Boehringer Ingelheim India. He replaces A Vaidheesh of GSK.
Moneycontrol
Like
Reply
Reputation: 3,179 • Mar 4 9:03 AM
Sridhar Venkatesh appointed as GSK India MD, VP
Venkatesh has more than 24 years of diverse experience in pharmaceuticals and healthcare, and has a strong track record of success in multiple roles within GSK, it added.
Moneycontrol
Like
Reply
Reputation: 3,179 • Feb 10 12:28 PM
Ranitidine recall forces GSK to alter Indian market strategy
GSK had initiated global voluntary recall of Ranitidine in September 2019, following reports of a probable cancer causing impurity called N‐nitrosodimethylamine (NDMA).
Moneycontrol
Like
Reply
GSK announces sale of Vemagal plant; takes Rs 640 crore hit on account of Zinetac recall - Times of India
Times of India brings the Latest & Top Breaking News on Politics and Current Affairs in India & around the World, Cricket, Sports, Business, Bollywood News and Entertainment, Science, Technology, Health & Fitness news & opinions from leading columnists.
The Times of India

Bad News for Pharmaceutical sector GlaxoSmithKline (GSK) Pharma - Bangalore
Yesterday night gave a very big Dinner in 5 star hotel to all Bangalore Employee & at the end of Dinner
GSK handed Termination Letter. With 6 months Salary Cheque.
GSK Pharma - Bangalore plant is clos...
Read more...
Like
Reply
Reputation: 3,022 • Feb 6 4:33 AM
GLAXO

Type
Sell
Instrument
GLAXO
Entry Price
₹1,362
Price@Trade
₹1,372.9
Target Price
₹1,330
Stop Price
₹1,388  ₹1,353
Valid Till
Feb 7, 2020 3:20 AM
Margin
₹1,362 approx for 1 Qty
Status
Exited
Exit Price
₹1,335.95
Net P&L
+₹26.01 (+1.91%)
Like
Reply (3)
Latest replies
TrackerBot @trackerbot
Feb 6 4:53 AM

Update
Trade Entered
Entry Price
₹1,362
JJ Technicals @jjtechnicals
Feb 6 5:51 AM

Update
Stoploss Trailed
Price @ Update
₹1,342
Original SL
₹1,388
New SL
₹1,353
JJ Technicals @jjtechnicals
Feb 6 5:55 AM

Update
Exited
Exit Price
₹1,335.95
Net P&L
+₹26.01 (+1.91%)
Reputation: 3,179 • Feb 5 11:13 AM
XLRI completes final placement in two days, average salary up by Rs 2 lakh at Rs 24.3 lakh pa
The final recruitment process saw participation from 108 recruiters with 362 domestic and international offers.
Moneycontrol
Like
Reply
Reputation: 3,179 • Feb 4 5:13 AM
GSK Pharma share price tanks 10% to hit 3-month low after Q3 loss of Rs 661 crore
The results were impacted due to voluntary global recall of ranitidine products, including Zinetac, said GlaxoSmithKline Pharmaceuticals Managing Director A Vaidheesh.
Moneycontrol
Like
Reply

GlaxoSmithKline Pharma plunges 13% on net loss of Rs 661 crore in Q3 - Business Standard
04-Feb-2020 09:53:09 AM
Shares of GlaxoSmithKline Pharmaceuticals tanked 13 per cent to Rs 1,429 on the BSE on Tuesday after the company reported a consolidated net loss of Rs 661 crore for ...
Read more...
Like
Reply
Reputation: 3,179 • Feb 3 2:18 AM
GlaxoSmithKline Pharma posts net loss of Rs 661.16cr for December quarter
The company had posted a net profit of Rs 113.67 crore for the corresponding period of the previous financial year, GlaxoSmithKline Pharmaceuticals said in a filing to the BSE.
Moneycontrol
Like
Reply
Reputation: -15,697 • Dec 24 8:55 AM

GSK PHARMA: LIC SELLS 34 LAKH SHARES (2% EQUITY) OF CO VIA OPEN MARKET ON DECEMBER 19
Like
Reply
Like
Reply

For the Job and Part time Traders 😘
This is one more simple example of Simplicity with out Charts ..
Glaxo bullish 1350 and see high 1703 in just 15 days so be in trend always
Like
Reply
Reputation: 7,516 • Oct 22 10:48 AM

Glaxo Pharma – Q2 FY20 (Unaudited – Cons.)
Share price – 1435
Total revenue from operations at 882.02 Cr
816.31 Cr (8.03%) YoY | 787.91 Cr (11.92%) QoQ
Six month ended revenue: 1669.9 Cr Vs. 1551.9 Cr (7.02%)
Net Profit of 502.7 Cr
100.8 Cr (402.43%) YoY 113.5 (345.07%) QoQ
Six...
Read more...
1
Reply
Reputation: 3,179 • Oct 22 10:43 AM
GSK Pharma Q2 profit at Rs 503 cr
Revenue from operations stood at Rs 882.02 crore for the quarter under review as against Rs 816.31 crore in the same period a year ago.
Moneycontrol
Like
Reply
Reputation: 3,179 • Oct 9 1:38 AM
Indian pharma market sees growth of 11.5% in Q2FY20
The July-October period saw outbreaks of infectious diseases in many parts of the country, aiding the growth of anti-infective segment to 14 percent YoY in the second quarter, beating overall IPM growth.
Moneycontrol
Like
Reply
Reputation: 3,179 • Oct 9 11:08 AM
Indian pharma market registers growth of 11.5% in Q2FY20
The July-October period saw outbreaks of infectious diseases in many parts of the country, aiding the growth of anti-infective segment to 14 percent YoY in the second quarter, beating overall IPM growth.
Moneycontrol
Like
Reply
Reputation: 3,179 • Sep 30 7:53 AM
Ranitidine controversy: Which Indian pharma companies stand to lose?
Moneycontrol
Like
Reply
Reputation: 3,179 • Sep 26 4:03 AM
GSK Pharma slips 5% after halting sale of acidity medicine Zinetac, other ranitidine products
The company has made the decision to initiate a voluntary recall of Zinetac Tablets 150 mg and 300 mg products manufactured in India.
Moneycontrol
Like
Reply
Reputation: 3,179 • Sep 26 1:58 AM
Stocks in the news: DHFL, Cipla, GSK Pharma, Sterlite Tech, Future Enterprises, CG Power, SRF
DHFL | Cipla | GlaxoSmithKline Pharma | Adani Enterprises | Future Enterprises and Sterlite Technologies are among stocks which are in news today.
Moneycontrol
Like
Reply
Reputation: 3,179 • Sep 26 1:43 AM
Stocks in the news: DHFL, Cipla, GSK Pharma, Adani Enterprises, Future Enterprises, CG Power, SRF
DHFL | Cipla | GlaxoSmithKline Pharma | Adani Enterprises | Future Enterprises and Sterlite Technologies are among stocks which are in news today.
Moneycontrol
Like
Reply
Reputation: 3,179 • Sep 26 1:18 AM
Stocks in the news: DHFL, Cipla, GSK Pharma, Adani Enterprises, Future Enterprises, Sterlite Tech
DHFL | Cipla | GlaxoSmithKline Pharma | Adani Enterprises | Future Enterprises and Sterlite Technologies are among stocks which are in news today.
Moneycontrol
Like
Reply
Reputation: 3,179 • Sep 25 2:18 AM
Trade Setup for Thursday: Top 15 things to know before Opening Bell
According to the pivot charts, key support level for Nifty is placed at 11,382.53, followed by 11,324.87. If the index starts moving up, key resistance levels to watch out for are 11,531.43 and 11,622.67.
Moneycontrol
Like
Reply
Reputation: 3,179 • Sep 25 12:28 PM
GSK suspends Ranitidine distribution in India, regulators seek drug testing data from pharma cos
Sources within pharma industry told Moneycontrol that Dr Reddy’s and Saraca Laboratories are two big suppliers of the Ranitidine active pharmaceutical ingredient (API) globally, from which most other companies source the API to formulate the drug.
Moneycontrol
Like
Reply
Like
Reply
Reputation: 1,414 • Sep 10 4:25 AM

CASH INTRADAY CALL (11 SEPT 2019)
GLAXO BUY ABOVE 1333M SL - 1321, TGT - 1364 & 1402
Like
Reply (1)
Latest replies
Tipu Pahan @tipupahan
Sep 11 3:47 AM

FROM 1333 TO 1400 (67 POINTS) PROFIT (+5% UP)
Reputation: 3,179 • Sep 9 11:33 AM
Pharma companies cheer good monsoon as demand for anti-infective drugs rises
Anti-infective drugs grew at 15.3 percent YoY in August, compared to Indian pharmaceutical market growth of 9.4 percent.
Moneycontrol
Like
Reply
Reputation: 3,179 • Sep 3 12:13 PM
Government scrambles to address shortage of rabies vaccine after GSK exit
Sources within the vaccine industry said that one of the main reasons for the current shortage was due to the exit of Chiron Behring Vaccines, a unit of GlaxoSmithKline (GSK).
Moneycontrol
Like
Reply
Reputation: 3,179 • Aug 21 3:29 AM
Focus on selective products, therapies starting to pay dividends: GSK Pharma
Vaidheesh hinted at new launches such as a vaccine (Bexsero) to protect infants against Meningitis B and a new drug to treat autoimmune disorders
Moneycontrol
Like
Reply
Reputation: 3,179 • Aug 7 9:38 AM
Hold GlaxoSmithKline Consumer Healthcare; target of Rs 7972: Prabhudas Lilladher
Prabhudas Lilladher recommended hold rating on GlaxoSmithKline Consumer Healthcare with a target price of Rs 7972 in its research report dated August 05, 2019.
moneycontrol.com
Like
Reply
Reputation: 3,179 • Jul 22 10:38 AM
Like
Reply
Reputation: 3,179 • Jul 15 2:38 AM
Like
Reply
Like
Reply
Reputation: 3,179 • Jul 10 7:53 AM
Like
Reply
Reputation: 3,179 • Jul 9 10:18 AM
Like
Reply
Reputation: 3,179 • Jun 14 3:18 AM
Like
Reply
Reputation: 3,179 • May 24 7:13 AM
Like
Reply

It will grow huge in next 2 days
Like
Reply
Join FrontPage
FrontPage is India's favorite stock discussions community
Join 50,000 Indian traders and discuss trades, strategies, news & views on any stock.
  • GLAXO - Share Price - Fundamentals

    keyboard_arrow_down
    Market Capitalization22,020.76
    Enterprise Value20,865.43
    Price to Earnings50.18
    Price to Book Value10.28
    Return on Capital Employed0.26
    Return on Equity0.17
    Face Value10
    Dividend Yield0.02
  • GLAXO - Brokerage Reports

    keyboard_arrow_down
    DateBrokerageCallTarget
    19-May-20Karvy Stock BrokingSell1,292
    21-May-19Motilal OswalNeutral1,350
    23-Oct-18CentrumSell950
    26-Jul-18CentrumSell950
    25-May-18Motilal OswalNeutral1,250
    GLAXO Brokerage Price Target
  • GLAXO Share Price - Historical (₹)

    keyboard_arrow_down
    DateOpenHighLowClose
    Jun 513781385.0513701382.3
    Jun 41383.9513901361.21372.95
    Jun 313641385.91355.11370.7
    Jun 21372.313891349.21356
    Jun 113901396.613661372.2
  • GLAXO Share Price - Daily Moving Averages (DMA)

    keyboard_arrow_down
    20 Day Moving Average₹1,380.74
    30 Day Moving Average₹1,404.82
    50 Day Moving Average₹1,364.12
    100 Day Moving Average₹1,407.74
    200 Day Moving Average₹1,442.5
  • GLAXO - Profit And Loss

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Revenue2,895.882,994.51-0.03
    Operating Profit508.44417.50.22
    Profit Before Tax541.58511.080.06
    Net Income351.99336.780.05
  • GLAXO - Balance Sheet

    keyboard_arrow_down
    CONSOLIDATEDMar-19Mar-18 % Change
    Shareholder's Funds2,1422,079.950.03
    Total Liabilities1,7671,901.27-0.07
    Total Assets3,9093,981.22-0.02
  • GLAXO - Cash Flow

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Cash from Operating Activity474.77233.131.04
    Cash from Investing Activity-107.01303.24-1.35
    Cash from Financing Activity-306.63-510.76-0.4
    Net Cash Flow61.1225.611.39
  • GLAXO - Ratios

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17
    Return on Assets0.090.11
    Return on Equity0.170.17
    Return on Capital Employed0.260.25
  • GLAXO - 3 year Growth

    keyboard_arrow_down
    3 Year CAGR Growth in Revenue-0.12
    3 Year CAGR Growth in Operating Profit-0.12
    3 Year CAGR Growth in EBIDTA-0.25
    3 Year CAGR Growth in Net Income-0.25
    3 Yr CAGR Growth - Diluted EPS-0.25
  • GLAXO - 5 year Growth

    keyboard_arrow_down
    5 Year CAGR Growth in Revenue0.1
    5 Year CAGR Growth in Operating Profit-0.24
    5 Year CAGR Growth in EBIDTA-0.33
    5 Year CAGR Growth in Net Income-0.39
    3 Yr CAGR Growth - Diluted EPS-0.39
  • GLAXO - Recent News

    keyboard_arrow_down
    NewsBot
    May 5 12:58 PM
    Hot Stocks | Glaxo Pharma, M&M, Tata Comm three buy ideas for short term
    Moneycontrol
    NewsBot
    Apr 15 12:38 PM
    Hot Stocks | Three stock ideas for the short term
    Moneycontrol
    NewsBot
    Apr 12 6:33 AM
    USFDA asks companies to remove ranitidine products; will Indian regulator review its stand?
    Moneycontrol
    NewsBot
    Mar 19 10:18 AM
    Coronavirus pandemic | Pharma companies ask sales representatives to work from home
    Moneycontrol
    NewsBot
    Mar 9 2:23 AM
    Pharma sales see rebound in February on back of respiratory drugs
    Moneycontrol
    NewsBot
    Mar 5 3:43 AM
    24 companies in BSE500 index reported net loss in Q3; what should you do with the stocks?
    Moneycontrol
    NewsBot
    Mar 4 11:18 AM
    MNC drug body OPPI names Sharad Tyagi as President
    Moneycontrol
    NewsBot
    Mar 4 9:03 AM
    Sridhar Venkatesh appointed as GSK India MD, VP
    Moneycontrol
    NewsBot
    Feb 10 12:28 PM
    Ranitidine recall forces GSK to alter Indian market strategy
    Moneycontrol
    NewsBot
    Feb 5 11:13 AM
    XLRI completes final placement in two days, average salary up by Rs 2 lakh at Rs 24.3 lakh pa
    Moneycontrol
  • GLAXO - Related Communities

    keyboard_arrow_down
    Sun Pharmaceutical Industries Ltd. NS...
    Aurobindo Pharma Ltd. NSE: AUROPHARMA...
    Cipla Ltd. NSE: CIPLA | BSE: 500087 |...
    Biocon Ltd. NSE: BIOCON | BSE: 532523...
    Lupin Ltd. NSE: LUPIN | BSE: 500257 |...
    Dr. Reddy's Laboratories Ltd. NSE: DR...
    Piramal Enterprises Ltd. NSE: PEL | B...
    Glenmark Pharmaceuticals Ltd. NSE: GL...
    Divi's Laboratories Ltd. NSE: DIVISLA...
    Apollo Hospitals Enterprise Ltd. NSE:...
SOURCE: Data from D'Market via Quandl. Intraday data delayed 15 minutes.
DISCLAIMER: Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and FrontPage will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein.

PrivacyTerms
FrontPage © 2020